Notably, both the GAD-7 and GAD-2 demonstrated acceptable diagnostic accuracy in detecting GAD with similar recommended cut-off scores as those reported in Western countries, but unacceptable diagnostic accuracy for other anxiety disorders.
To investigate the association of GAD (65-kDa) autoantibodies (GAD65-Abs) and IA-2 autoantibodies (IA-2-Abs) with human leukocyte antigen (HLA)-DQ and insulin gene (INS) risk markers in patients with recent-onset IDDM and their siblings.
The best cut-off points to obtain high sensitivity values was 3, on both the PHQ-2 (major depressive disorder) and the GAD-2 (generalized anxiety disorder).
Screening uses validated measures (Tobacco, Alcohol, Prescription medication, and other Substance use [TAPS]; and the Adult Outcomes Questionnaire [AOQ], which includes the Patient Health Questionnaire [PHQ-9] and Generalized Anxiety Disorder [GAD-2]) delivered via three modalities (secure messaging, tablets in waiting rooms, and desktop computers in exam rooms).
In contrast, children who were single GADA positive often had lower affinity GADA and/or GADA with specificities that were restricted to minor NH(2)-terminal GAD65 epitopes.
Patients reported on perceived changes in health outcomes as measured by <i>Short-Form Health Survey</i> (<i>SF-12</i> general, mental, and physical health), <i>Perceived Stress Scale (PSS4)</i>, <i>Work Productivity and Activity Impairment Questionnaire (WPAI)</i>, <i>World Health Organization Well-Being Index (WHO-5</i>), <i>Pain Visual Analog Scale (VAS)</i>, <i>Fatigue Severity Scale (VAS; FSS)</i>, <i>Generalized Anxiety Disorder Scale (GAD2)</i>, <i>Patient Health Questionnaire</i> for depression <i>(PHQ2), Pittsburgh Sleep Quality Index (PSQI)</i> global rating of sleep quality, and the <i>Behavioral Risk Factor Surveillance System (BRFSS</i>; nutrition, exercise, and physical activity).
The effectiveness of ultra-short versions of the NDDI-E (2 items) and the GAD-7 (the GAD-2, 2 items, and the GAD-SI with a single item) in comparison with the original versions were statistically tested using ROC analysis.
In total, 211 patients with HS completed the Brief Illness Perception Questionnaire (BIPQ), the Patient's Health Questionnaire-2 (PHQ-2), the Generalized Anxiety Disorder-2 (GAD-2) and the Dermatology Life Quality Index (DLQI).
Anchors included patient health questionnaire 9-items "PHQ9" and generalized anxiety disorder 2-item questionnaire "GAD2" for EQ-5D-3L, and PHQ9 and SF-12 mental composite summary scores (MCS) for EQ-5D-5L.
A random sample of 688 undergraduate university students (mean age = 20.64 ±1.88 years; 53% men) completed a survey composed of a) questions about socio-demographics, academics, lifestyle behaviors, personality type, and smartphone use-related variables; b) 26-item Smartphone Addiction Inventory (SPAI) Scale; and c) brief screeners of depression and anxiety (PHQ-2 and GAD-2), which constitute the two core DSM-IV items for major depressive disorder and generalized anxiety disorder, respectively.